# UC Davis IGA Innovation Center

> **NIH FDA U18** · UNIVERSITY OF CALIFORNIA AT DAVIS · 2024 · $1,000,000

## Abstract

We propose to establish the “UC Davis Intentional Genomic Alteration (IGA) Innovation
Center” focused on research on IGAs in major livestock species to advance the use of gene
editing technologies in food animals, while generating and sharing both phenotypic and
bioinformatic data to support a science-based approach to the regulation of IGAs in food animals.
UC Davis has long been a leader in applying genetic technologies to farm animal species and we
are uniquely positioned to address issues surrounding the use of gene editing in animals destined
for the food chain due to the depth and breadth of extant food animals (cattle, pigs, sheep, and
goats) with IGAs we have generated, and the pipeline we have planned for the future. These
animals have been produced for both agricultural and biomedical purposes over the past 20
years, with gene edited animals predominating in the past 5 years. This inventory includes
genetically engineered and gene-edited knockout and knock-in animals resulting from both
microinjection and electroporation, some of which have multiple generations of offspring. The
specific aims of this Cooperative Agreement are:
Aim 1: To develop a gold standard workflow for assessing on- and off-target events as a
result of gene editing. Whole genome sequencing (WGS), in vitro and in silico approaches to
detect on- and off-target events will be compared to establish a strategy that will account for
natural sequence variability, sequencing depth and bioinformatics workflows to ensure accurate
identification of on- and off-target changes in the genome.
Aim 2: To document the genotypic and phenotypic durability of IGAs across generations
and species. Genotypic durability of on- and off-target events will be documented in gene edited
cattle, pigs, and sheep and, bovine embryonic stem cells (bESCs) and phenotypic durability
assessed including compiling information on known variation in nutrient profiles of products
derived from food animals to help inform design of experiments to explicitly evaluate alterations
in product composition.
Aim 3: To assess the reproducibility of various gene editing platforms including prime
editing in terms of efficacy of editing and presence of off-target cutting in different cell types.
We anticipate sharing the materials and data we produce with FDA scientific or program staff and
coordinating project activities with the FDA to provide evidence to address regulatory questions
to help advance the safe use of gene editing to improve the sustainability of animal agriculture,
and facilitate more FDA-regulated products coming to market.

## Key facts

- **NIH application ID:** 11162200
- **Project number:** 1U18FD008480-01
- **Recipient organization:** UNIVERSITY OF CALIFORNIA AT DAVIS
- **Principal Investigator:** Trish Berger
- **Activity code:** U18 (R01, R21, SBIR, etc.)
- **Funding institute:** FDA
- **Fiscal year:** 2024
- **Award amount:** $1,000,000
- **Award type:** 1
- **Project period:** 2024-09-15 → 2029-09-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11162200

## Citation

> US National Institutes of Health, RePORTER application 11162200, UC Davis IGA Innovation Center (1U18FD008480-01). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/11162200. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*